Over half of U.S. adults (52%) think the vaccine given to pregnant individuals to protect their infants from RSV (respiratory syncytial virus) is effective, up from 42% in October 2023, soon after the Centers for Disease Control and Prevention (CDC) recommended the vaccine. And 61% say the RSV vaccine for adults age 60 and older is effective, up from 54% in October 2023.

Survey Methodology

The Annenberg Public Policy Center of the University of Pennsylvania (APPC) engaged SSRS to conduct the 22nd Wave of the Annenberg Survey of Attitudes on Public Health (ASAPH) National Survey. This survey wave focused on respondents’ knowledge and experience with viruses such as COVID-19, whooping cough (pertussis), and the flu, as well as respondents’ opinions on science and medical science.

The Wave 22 survey invited U.S. adults aged 18 and older who had completed the ASAPH Wave 1 survey in April 2021, who were recruited in ASAPH Wave 9 or the ASAPH Engagement Survey (both conducted in 2023), or who were recruited during the August 2024 Replenishment, to participate. Only panelists who had previously reported not being members of other U.S. opinion panels were invited. The invited sample size (i.e., the full panel size) was N = 2,589.